Stay updated on Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial

Sign up to get notified when there's something new on the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:25:52.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new clinical trial involving nivolumab, ipilimumab, and panitumumab for treating unresectable refractory KRAS/NRAS/BRAF wild-type metastatic colorectal cancer, with a new principal investigator, Hanna K Sanoff, MD, and collaborators Amgen and Bristol-Myers Squibb.
    Difference
    48%
    Check dated 2025-04-16T20:39:07.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 13, 2025, while a date for March 25, 2025, has been removed.
    Difference
    0.2%
    Check dated 2025-04-09T14:50:03.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The webpage has updated its scheduling information, with new dates added for events in 2025 and the removal of previous estimated dates.
    Difference
    1%
    Check dated 2025-03-18T14:33:56.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T23:04:39.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T16:37:43.000Z thumbnail image

Stay in the know with updates to Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page.